Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
5(83%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
17%
Ph phase_3
5
83%

Phase Distribution

0

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
5(83.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Completed(1)

Detailed Status

Recruiting5
Completed1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (16.7%)
Phase 35 (83.3%)

Trials by Status

completed117%
recruiting583%

Recent Activity

5 active trials
Showing 5 of 6
recruitingphase_3

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06966401
recruitingphase_3

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06963021
recruitingphase_3

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT07196501
recruitingphase_3

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06911112
recruitingphase_3

Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06786624
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06966401Phase 3

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Recruiting
NCT06963021Phase 3

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Recruiting
NCT07196501Phase 3

A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Recruiting
NCT06911112Phase 3

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Recruiting
NCT06786624Phase 3

Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Recruiting
NCT05203341Phase 2

Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6